AVA6207

AVA6207 is a first-in-class dual-payload peptide drug conjugate (PDC) being developed by Avacta Group using its proprietary pre|CISION platform. The therapeutic is designed to target the tumor microenvironment by specifically binding to and being cleaved by fibroblast activation protein (FAP), which is overexpressed in many solid tumors. AVA6207 delivers two distinct therapeutic payloads simultaneously through a single FAP-mediated cleavage event: exatecan (a topoisomerase I inhibitor) and a DNA damage repair (DDR) inhibitor, such as a PARP inhibitor. This dual-action approach is intended to provide synergistic anti-tumor efficacy by interfering with DNA replication and blocking subsequent repair mechanisms, while the tumor-selective release minimizes systemic exposure and toxicity. It is currently in preclinical development for the treatment of solid tumors.